UPDATE 1-US appeals court affirms ruling on Risperdal patent

Fri May 11, 2007 5:52pm BST

Related Topics



(Adds background)

WASHINGTON May 11 (Reuters) - A U.S. appeals court upheld a lower court ruling on Friday that blocked U.S. sales of two copycat versions of the Johnson & Johnson (JNJ.N) antipsychotic drug Risperdal until a J&J patent expires at the end of 2007.

The U.S. Court of Appeals for the Federal Circuit affirmed rulings by a lower court judge in New Jersey that upheld the validity of a key J&J patent on the drug and delayed the effective date of a tentative approval given to Mylan Pharmaceuticals Inc. , a unit of Mylan Laboratories Inc. MYL.N to market its generic Risperdal.

Risperdal generated sales of about $3 billion in 2005.

A lawsuit filed by J&J unit Janssen LP in December 2003 alleged Mylan and India's Dr. Reddy's Laboratories Ltd. (REDY.BO) infringed the Risperdal patent.

Risperdal was approved in 1993 and is marketed as a treatment for schizophrenia, mania associated with manic depression and irritability associated with autism in children and adolescents.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.